Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,094 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonality of HIV-1- and HTLV-1-Infected Cells in Naturally Coinfected Individuals.
Katsuya H, Cook LBM, Rowan AG, Melamed A, Turpin J, Ito J, Islam S, Miyazato P, Jek Yang Tan B, Matsuo M, Miyakawa T, Nakata H, Matsushita S, Taylor GP, Bangham CRM, Kimura S, Satou Y. Katsuya H, et al. Among authors: nakata h. J Infect Dis. 2022 Jan 18;225(2):317-326. doi: 10.1093/infdis/jiab202. J Infect Dis. 2022. PMID: 33844021
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H. Maeda K, et al. Among authors: nakata h. J Virol. 2004 Aug;78(16):8654-62. doi: 10.1128/JVI.78.16.8654-8662.2004. J Virol. 2004. PMID: 15280474 Free PMC article.
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. Nakata H, et al. J Virol. 2005 Feb;79(4):2087-96. doi: 10.1128/JVI.79.4.2087-2096.2005. J Virol. 2005. PMID: 15681411 Free PMC article.
Structural and molecular interactions of CCR5 inhibitors with CCR5.
Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H. Maeda K, et al. Among authors: nakata h. J Biol Chem. 2006 May 5;281(18):12688-98. doi: 10.1074/jbc.M512688200. Epub 2006 Feb 13. J Biol Chem. 2006. PMID: 16476734 Free article.
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y, Yuki H, Hirata S, Ide K, Nakata H, Miyakawa T, Matsuno N, Nosaka K, Yonemura Y, Kawaguchi T, Hata H, Mitsuya H, Okuno Y. Kikukawa Y, et al. Among authors: nakata h. Int J Hematol. 2015 Feb;101(2):133-9. doi: 10.1007/s12185-014-1705-9. Epub 2014 Nov 28. Int J Hematol. 2015. PMID: 25430082
Various associations of aging and long-term HIV infection with different neurocognitive functions: detailed analysis of a Japanese nationwide multicenter study.
Komatsu K, Kinai E, Sakamoto M, Taniguchi T, Nakao A, Sakata T, Iizuka A, Koyama T, Ogata T, Inui A, Oka S; HIV-Associated Neurocognitive Disorders in Japanese (J-HAND) Study Group (The J-HAND Study Group). Komatsu K, et al. J Neurovirol. 2019 Apr;25(2):208-220. doi: 10.1007/s13365-018-0704-7. Epub 2019 Mar 11. J Neurovirol. 2019. PMID: 30859496
Erratum to: Clonality of HIV-1- and HTLV-1-Infected Cells in Naturally Coinfected Individuals.
Katsuya H, Cook LBM, Rowan AG, Melamed A, Turpin J, Ito J, Islam S, Miyazato P, Jek Yang Tan B, Matsuo M, Miyakawa T, Nakata H, Matsushita S, Taylor GP, Bangham CRM, Kimura S, Satou Y. Katsuya H, et al. Among authors: nakata h. J Infect Dis. 2022 Jan 18;225(2):359. doi: 10.1093/infdis/jiab493. J Infect Dis. 2022. PMID: 34865054 No abstract available.
Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates.
Matsumoto K, Kuwata T, Tolbert WD, Richard J, Ding S, Prévost J, Takahama S, Judicate GP, Ueno T, Nakata H, Kobayakawa T, Tsuji K, Tamamura H, Smith AB 3rd, Pazgier M, Finzi A, Matsushita S. Matsumoto K, et al. Among authors: nakata h. J Virol. 2023 Jan 31;97(1):e0163822. doi: 10.1128/jvi.01638-22. Epub 2022 Dec 13. J Virol. 2023. PMID: 36511698 Free PMC article.
1,094 results